Adocia Prioritizes BioChaperone and Secures Cash Reserves Until Early Q2 2027
Adocia has released its Q1 2026 financial results, showing a cash balance of EUR 12.0 million as of March 31, with a quarterly cash burn of EUR 5.1 million. As typical for a clinical-stage biotech, revenue was zero for the period, compared to EUR 0.6 million a year earlier from an AdOral feasibility study. The Lyon-based company is reallocating its resources towards BioChaperone, now a priority following positive feasibility study results, and has suspended the clinical trial application submission for AdoShell. A EUR 6.0 million financing arrangement with Vester Finance extends its cash runway until the start of Q2 2027.
Adocia had a cash reserve of EUR 12.0 million on March 31, 2026, down from EUR 17.2 million on December 31, 2025. The cash burn for the first quarter amounted to EUR 5.1 million, compared to EUR 6.6 million in the first quarter of 2025 excluding financing. Revenue for the period was zero, down from EUR 0.6 million a year earlier.
This decline should be viewed in the context of the economic model of a clinical-stage biotech: revenues are inherently irregular and depend largely on partnerships, milestone payments, or feasibility studies. In the first quarter of 2025, revenues came from a feasibility study related to the AdOral technology with an undisclosed partner.
BioChaperone Becomes the Strategic Priority
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The major shift announced by Adocia concerns its resource allocation. The company now prioritizes the BioChaperone platform, following positive results from feasibility studies and the initiation of a new study. This platform aims to stabilize and enhance metabolic peptide formulations, in a market where diabetes and obesity treatments are moving towards peptide combinations, particularly involving GLP-1 and amylin. Adocia has initiated feasibility studies with three major undisclosed pharmaceutical companies, two of which have yielded positive results.
AdoShell Suspended, But Not Abandoned
In parallel, Adocia has suspended activities related to the clinical trial application submission for AdoShell with human pancreatic islets, initially planned for the third quarter of 2026. The company explains this decision by the priority given to BioChaperone and the need to reallocate its human and financial resources to this technology. However, the AdoShell program is not presented as abandoned: Adocia indicates that it could resume this clinical goal when its financial situation and human resources allow.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 2T2026
Key reported figures
Revenue: 43K€
Guidance from the release
« Au cours de ce trimestre, nous avons continué d’avancer, avec notre partenaire Tonghua Dongbao, vers le dépôt de la demande d’autorisation de mise sur le marché en Chine de BioChaperone® Lispro. »
Le chiffre d'affaires du trimestre, limité à 43 K€, provient d'une étude de faisabilité sur la technologie BioChaperone® pour un partenaire non divulgué. La trésorerie s'établit à 9,7 M€ au 30 juin 2026 contre 17,2 M€ fin 2025. La Société recentre ses priorités sur BioChaperone®, met en pause M1Pram après l'expiration du droit exclusif de négociation de Sanofi et suspend la demande d'essai clinique d'AdoShell®.
Risks mentioned
Horizon de trésorerie limité au début du deuxième trimestre 2027
Trésorerie en baisse à 9,7 M€ au 30 juin 2026 contre 17,2 M€ fin 2025
Expiration du droit exclusif de négociation de Sanofi sur M1Pram et mise en pause du programme
Suspension de la demande d'essai clinique AdoShell® faute de ressources financières et humaines
Opportunities identified
Dépôt en préparation de la demande d'AMM en Chine de BioChaperone® Lispro par Tonghua Dongbao
Paiement d'étape de 20 millions de dollars US conditionné à l'AMM chinoise, plus redevances à deux chiffres
Discussions de prochaines étapes engagées avec deux grandes sociétés pharmaceutiques sur BioChaperone®
Nouvelle plateforme brevetée AdoXLong™ visant une injection mensuelle, protection potentielle jusqu'en 2046
Bons de souscription pouvant générer jusqu'à 10,2 et 11,5 millions d'euros en cas de hausse du cours
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
